Quality of life in children with psoriasis
|
|
- Zoe Warren
- 5 years ago
- Views:
Transcription
1 Quality of life in children with psoriasis Marieke Seyger Psychodermatologie: het kind centraal Vrijdag 23 januari 2015 AMC Amsterdam
2 Disclosure Has received research grants from / was involved in clinical trials from Abbvie, Almirall, Astellas, Leo Pharma and Pfizer Served as a consultant for Abbvie, Almirall, Astellas, Boehringer Ingelheim, Celgene and Pfizer
3 Kinder Psoriasis - Adulte Psoriasis Bei Kindern: >> positive Familienanamnese >> HLA-Cw6 positiv >> Genitalregion, Kopfhaut und Gesicht >> Oberflächlichkeit der Plaques Mehr Juckreiz! Viel Off-label-Anwendung Mehr Einschränkung der Lebensqualität??
4 Contents CDLQI An intrapatient comparison of QoL in psoriasis in childhood and adulthood Influence of treatments on Qol in pediatric psoriasis SPECTRUM program
5 CDLQI = Children s Dermatology Life Quality Index Score: 0-30
6 Quality of life in childhood psoriasis Children s Dermatology Life Quality Index (CDLQI;0-30) Lewis Jones et al: 1 Psoriasis (n= 25) CDLQI = 5.4 SD 5.0 Beattie et al: 2 Psoriasis (n=29) CDLQI = 9.17 SD 7.83 Eczema (n=106) CDLQI = 9.14 SD 6.69 Urticaria (n=17) CDLQI = 6.12 SD 6.39 Acne (n= 50) CDLQI = 5.4 SD 4.69 Nijmegen Registry (n=290) CDLQI = 7.5 SD Lewis-Jones et al. Br.J. Dermatol 1995;132: Beattie et al. Br.J.Dermatol 2006; 155: pp
7 An intrapatient comparison of quality of life in psoriasis in childhood and adulthood. A Questionnaire among 1762 adult patients M.E.A. de Jager, E.M.G.J. de Jong, P.C.M. van de Kerkhof, A.W.M. Evers, M.M.B. Seyger. J Eur Acad Dermatol Venereol. 2011;25(7):
8 568 adult patients (32.2%) had childhood onset psoriasis Retrospectively adults assess childhood QoL much more impaired than adulthood QoL ( DLQI: 12.8 vs 6.8) In % of patients childhood psoriasis had a high degree of limitations on recreational and social activities The social development-domain, which is one of the developmental milestones in a child, is particularly impaired The QoL on the long term is not determined by the age of onset of psoriasis. (DLQI COP 6.8 vs DLQI AOP 6.9)
9 Evaluate the age at diagnosis on the liftime outcomes of psoriasis patients Those diagnosed at younger age: (n = 26) More likely to have a greater lifetime DLQI Have felt depressed Believe that psoriasis had caused their depression Experience life time sleep problems Use recreational drugs Hide their psoriasis over their lifetime Experience more lifetime discrimination in social settings Pediatric dermatology 2014
10 Quality of life in childhood psoriasis
11 Aim To investigate the influence of treatments in daily clinical practice on the Children s Dermatology Life Quality Index (CDLQI) in pediatric psoriasis To assess what items of the CDLQI were mainly influenced by psoriasis treatments.
12 Child-CAPTURE Nijmegen Registry (since 2008) Continuous Assessment Psoriasis Treatment Use Registry Prospective observational registry: 290 children (<18) included Efficacy and safety of treatments Clinical parameters Quality of life Genetic research
13 Child-CAPTURE - Referrals
14 Results Cohort characteristics Number of patients 125 Mean age (range) 10.7 years (3-17) Female gender 63.2% Psoriasis history Mean duration (range) 39.2 months (1-154) Family history 70.4% Baseline assessments Mean CDLQI (range) 7.5 (0-25) Mean PASI (range) 7.0 (0-33.3)
15
16 Results Cross-sectional
17 Results - Cross-sectional Age differences * * * *
18 Results - Longitudinal * * * *
19 Results - Longitudinal
20
21 Supportive Program for Education, Coping en Training of parents and children with psoriasis Aim: show children and adolescents different ways how to cope with psoriasis in daily life Dermatology Nurse Medical Psychologist Dermatologist SPECTRUM
22
23 SPECTRUM Two age-related groups: 6-12 years; years Three sessions (± 3 hours) One follow-up session Small group size (5-6 patients)
24 SPECTRUM - CONTENT 1. Medical information Daily skin care 2. Recognition and avoidance of trigger factors for itch and scratching Dealing with itching and scratching 3. Coping with psoriasis, including confidence and self-esteem Sleep hygiene and relaxation exercises 4. Long-term goals and relapse prevention
25 SPECTRUM - EVALUATION 1. Medical information Daily skin care 2. Recognition and avoidance of trigger factors for itch and scratching Dealing with itching and scratching 3. Coping with psoriasis, including confidence and self-esteem Sleep hygiene and relaxation exercises 4. Long-term goals and relapse prevention Overall score 23 Children: 8 22 Parents: 9
26 Conclusions Pediatric psoriasis has a negative impact on QoL Retrospectively adults assess childhood QoL much more impaired than adulthood QoL ( DLQI: 12.8 vs 6.8) In % of patients childhood psoriasis had a high degree of limitations on recreational and social activities The social development-domain, which is one of the developmental milestones in a child, is particularly impaired Itch and treatment have the highest impact on QoL Treatment especially improves itch and sleep disturbance SPECTRUM program could be a promising addition to regular treatment
27 The Pediatric Psoriasis Team Dermatology Maartje van Geel Inge Bronckers Annet Oostveen Michelle de Jager Elke de Jong Peter van de Kerkhof Wilma Klompmaker Maria Teunissen Judith Bergboer Joost Schalkwijk Patrick Zeeuwen Medical Psychology Andrea Evers Saskia Spillekom-van Koulil Pediatric Rheumatology Esther Hoppenreijs Radboud University Nijmegen Medical Centre, The Netherlands
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? THERAPEUTICS
THERAPEUTICS BJD British Journal of Dermatology Happy drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network J.M.P.A. van den Reek,
More informationDLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
More informationEffectiveness of a Multidisciplinary Itch-coping Training Programme in Adults with Atopic Dermatitis
Acta Derm Venereol 29; 89: 57 63 CLINICAL REPORT Effectiveness of a Multidisciplinary Itch-coping Training Programme in Adults with Atopic Dermatitis Andrea W. M. Evers 1,2, Piet Duller 1,2, Elke M. G.
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationP4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling
P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling Mark Lebwohl, 1 Andrew Blauvelt, 2 Matthias Augustin, 3 Yang Zhao, 4 Isabelle Gilloteau,
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationAssociation between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry
4385 Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4,
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationFirst Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis
5137 First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the Study: An Interim Analysis Kristian Reich, MD 1 ; Stefanie Bomas, MD 2 ; Bernhard Korge, MD 3 ; Maria Manasterski,
More informationSymptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission
Symptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission 93 Korman, NJ 1, Zhao, Y 2, Roberts, J 3 Pike, J 3, Lu, J 2, Tran, MH 2 (Please see
More informationEVALUATION OF THERAPEUTIC PROGRAMS EDUCATING AD PATIENTS AND THEIR PARENTS
EVALUATION OF THERAPEUTIC PROGRAMS EDUCATING AD PATIENTS AND THEIR PARENTS Rencontres 2èmes Internationales sur l Él Éducation Thérapeutique dans la Dermatite Atopique Rome, le 1er juillet 2011 Danielle
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? GENERAL DERMATOLOGY
GENERAL DERMATOLOGY BJD British Journal of Dermatology Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective,
More informationReceived: June 29, 2006 Revised: August 15, 2006 Accepted: August 30, 2006
Quality J Microbiol of life Immunol in atopic Infect. dermatitis patients 7;4:6-64 Quality of life in atopic dermatitis patients Original Article Habibeh Mozaffari, Zahra Pourpak,, Sara Pourseyed, Abolhasan
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3,
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationAbstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
More informationThe Potential Psychological Impact of Skin Conditions
DOI 10.1007/s13555-016-0169-7 REVIEW The Potential Psychological Impact of Skin Conditions Ari Tuckman Received: August 11, 2016 The Author(s) 2017. This article is published with open access at Springerlink.com
More informationThe Burden of Atopic Dermatitis: from Population to Bedside
The Burden of Atopic Dermatitis: from Population to Bedside S028 AAD Annual Meeting March 2, 2019 Research and institutional funding Sanofi Regeneron Disclosures Consultant Honoraria Sanofi Astellas Canada
More informationEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
More informationDoes the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?
DOI: 10.1111/jdv.15226 JEADV ORIGINAL ARTICLE Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? A. Langenbruch,* M.A. Radtke, M. Gutknecht,
More informationPsoriasis Disease Severity Affects Patient Satisfaction With Therapy
82 Psoriasis Disease Severity Affects Patient Satisfaction With Therapy Korman NJ 1, Zhao Y 2, Tran MH 2, Lu J 2 (Please see authors affiliations on the last panel) Background Psoriasis is a chronic, immune
More informationDeveloping a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis A Step Toward Personalized Treatment
Research Original Investigation Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis A Step Toward Personalized Treatment Stef P. Menting, MD; Emma Coussens, MD;
More informationFROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A HOLISTIC PERSPECTIVE OF PSORIASIS TREATMENT
FROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A HOLISTIC PERSPECTIVE OF PSORIASIS TREATMENT This symposium took place on 15 th September 2017 as a part of the 26th European Academy of Dermatology and Venereology
More informationRunning head: ATOPIC DERMATITIS, ITS IMPACT AND TREATMENT
Atopic Dermatitis, Its Impact and Treatment Running head: ATOPIC DERMATITIS, ITS IMPACT AND TREATMENT The Impact of Treatment on Quality of Life of Children with Atopic Dermatitis and their Families Consuela
More informationQUALITY OF LIFE AMONG ADULT PATIENTS WITH PSORIASIS
e-poster No. P2498 22 nd World Congress of Dermatology, Seoul 2011 QUALITY OF LIFE AMONG ADULT PATIENTS WITH PSORIASIS A study using data from the Malaysian Psoriasis Registry Choong-Chor Chang 1, Felix
More informationAYPH conference Young peoples experiences of skin conditions Tess McPherson Consultant dermatologist Oxford
Skin, Stigma, Services & Support AYPH conference Young peoples experiences of skin conditions Tess McPherson Consultant dermatologist Oxford Skin Skin problems major problem in young people Skin condition
More informationMonth/Year of Review: January 2015 Date of Last Review: January 2010
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationCorrelation between Severity of Atopic Dermatitis and Sleep Quality in Children and Adults
Severity of AD and Sleep Quality pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 28, No. 3, 2016 http://dx.doi.org/10.5021/ad.2016.28.3.321 ORIGINAL ARTICLE Correlation between Severity of Atopic Dermatitis
More informationEffect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial
1152 Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial April W. Armstrong, MD, MPH 1 ; Christopher E.M. Griffiths, MD 2 ; Tom
More informationJournal of Nobel Medical College
ISSN: 2091-2331 (PRINT) 2091-234X (ONLINE) Journal of Nobel Medical College Available Online: www.nepjol.info, www.nobelmedicalcollege.com.np Volume 7, Number 1, Issue 12, January-June 2018, 45-49 Original
More informationPASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough?
PASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough? This symposium took place on 14 th September 2018, as part of the 27 th European Academy of Dermatology
More informationSTUDY. Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
STUDY Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis Lidian L. A. Lecluse, MD; Rieke J. B. Driessen, MD; Phyllis I. Spuls, MD, PhD; Elke M.
More informationSummer AAD Summer AAD Support provided by LEO Pharma A/S. Poster nº
Support provided by LEO Pharma A/S Fixed combination calcipotriene plus betamethasone dipropionate aerosol foam provides improvement in quality of life and rapid relief of itch/itch-related sleep loss
More informationClinical profile of skin diseases in accident and emergency department attenders
Hong Kong J. Dermatol. Venereol. (2007) 15, 4-9 Original Article Clinical profile of skin diseases in accident and emergency department attenders CY Chan, KL Kam, CA Graham, TH Rainer, NM Luk Skin problems
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationDermatology Life Quality Index: Data from Danish Inpatients and Outpatients
Acta Derm Venereol 2000; 80: 272±276 CLINICAL REPORT Dermatology Life Quality Index: Data from Danish Inpatients and Outpatients ROBERT ZACHARIAE 1, CLAUS ZACHARIAE 2, HANS IBSEN 3, JANNE TOUBORG MORTENSEN
More informationJEADV SHORT REPORT. Abstract
DOI: 10.1111/jdv.15258 JEADV SHORT REPORT Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled
More informationTraining on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units
Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units This PsA assessment initiative is led by the UK PsA Assessment Academy and funded by
More informationOngoing care for people with skin diseases can be optimized by. Skin Diseases in Family Medicine: Prevalence and Health Care Use
Skin Diseases in Family Medicine: Prevalence and Health Care Use Elisabeth W. M. Verhoeven, MSc 1 Floor W. Kraaimaat, PhD 1 Chris van Weel, PhD 2 Peter C. M. van de Kerkhof, PhD 3 Piet Duller, MSc 1,3
More informationHealth-related Quality of Life in Children with Moderate to Severe Atopic Dermatitis
2015;23(3):178-184 CLINICAL ARTICLE Health-related Quality of Life in Children with Moderate to Severe Atopic Dermatitis Milena Ražnatović Djurović 1, Janko Janković 2, Vesna Tomić Spirić 3, Slavenka Janković
More informationKenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 1.1111/jdv.14878 JEADV ORIGINAL ARTICLE Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-tosevere psoriasis through 5 years of treatment (SCULPTURE
More informationREVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS
REVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS Summary of Presentations from the Novartis-Supported Satellite Symposium, held at the 23 rd EADV Congress, Amsterdam, the Netherlands,
More informationAccepted Article. Frequency of and predictors for a high clinical response in psoriasis patients on biologic therapy in daily practice
Received Date : 11-Apr-2016 Revised Date : 15-Jul-2016 Accepted Date : 15-Jul-2016 Article type : Original Article Frequency of and predictors for a high clinical response in psoriasis patients on biologic
More informationUNDERSTANDING ATOPIC DERMATITIS IN AUSTRALIA
Key points: Australia has a high lifetime prevalence of atopic dermatitis (AD) of around 32%. The country relies on regional Asia-Pacific guidelines for AD, which lack recommendations around the use of
More informationEmerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis
Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis These posters were presented at the 5 th World Psoriasis & Psoriatic Arthritis Conference 2018, held from 27 th 30 th June in Stockholm,
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationDermatology Literary Review
Emollients and ageing skin: optimising effectiveness and safety of Nursing, Vol. 25, No.11, pages 596-598. 6 Article outlines the causes of dryness in ageing skin and concludes that emollients are the
More informationManagement of Senile Atopic Dermatitis in Geriatric Outpatient Clinic Dermatovenereology Department Ciptomangunkusumo Hospital in
Global Journal of Medical Research: F Diseases Volume 18 Issue 2 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Online ISSN: 2249-4618 & Print ISSN:
More informationBody Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab
Am J Clin Dermatol (16) 17:691 699 DOI 1.7/s257-16-229-x ORIGINAL RESEARCH ARTICLE Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab April
More informationInitiation and evaluation of the effect of biologic treatment. ActaDV ActaDV
CLINICAL REPORT 1 Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab Jeanette Halskou HESSELVIG, Alexander EGEBERG,
More informationEXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS
EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS ACTIVITY 1: EARLY COLLABORATION IN THE TREATMENT OF PSA Key Slides COMMON COMORBIDITIES OF PSORIATIC DISEASE
More informationApproximately 3% of the US adult population,
Disease Burden and Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Results From National Psoriasis Foundation Panel Surveys Emily Edson-Heredia, MPH; Baojin Zhu, PhD;
More informationBJD British Journal of Dermatology. Summary MEDICAL DERMATOLOGY
MEDICAL DERMATOLOGY BJD British Journal of Dermatology Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results
More informationReal-life data demonstrate the potential of methotrexate in severe and moderately severe psoriasis
14.09.2018 Page 1 / 5 Medac at the EADV Congress Real-life data demonstrate the potential of methotrexate in severe and moderately severe psoriasis First French guidelines for psoriasis therapy - subcutaneous
More informationAssessing quality of life in sarkoma trials
Pan-European Clinical Trials under current EU regulations: A training course for data managers, study nurses, and junior clinical investigators London, January 24/25, 2008 Assessing quality of life in
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationPRURI. meter Prof. Dr. med. Matthias Augustin Prof. Dr. med. Marc A. Radtke Prof. Dr. med. Dr. h.c. Sonja Ständer
PRURI meter Prof. Dr. med. Matthias Augustin Prof. Dr. med. Marc A. Radtke Prof. Dr. med. Dr. h.c. Sonja Ständer PRURITUS in Psoriasis Facts Epidemiology 90% of psoriasis patients report pruritus To be
More informationGenital Psoriasis Awareness Program: Physical and Psychological Care for Patients with Genital Psoriasis
Acta Derm Venereol 2015; 95: 211 216 CLINICAL REPORT Genital Psoriasis Awareness Program: Physical and Psychological Care for Patients with Genital Psoriasis Kim A. P. Meeuwis 1,2, Joanne A. de Hullu 2,
More informationPGA x BSA as a PASI Surrogate
PGA x BSA as a PASI Surrogate Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationPatients Perspective on the Impact of Moderate-to-Severe Genital Psoriasis
4664 Patients Perspective on the Impact of Moderate-to-Severe Genital Psoriasis Jennifer Clay Cather, 1 Alison Potts Bleakman, 2 April Naegeli, 2 Jiat Ling Poon, 3 Ashley Wallace, 4 Kristin Hollister,
More informationChange/Insert Date & Location via >Insert >Header & Footer To view drawing guides
Patient profiling Who is your patient and what do they want to hear? What are your patient s ideas, concerns, expectations (ICE)? How much do they already know about their psoriasis? Is your patient more
More informationOptimizing Topical Therapy In Atopic Dermatitis
Optimizing Topical Therapy In Atopic Dermatitis Steven R. Feldman, MD, PhD Professor of Dermatology, Pathology & Public Health Sciences Wake Forest University School of Medicine Winston-Salem, North Carolina,
More informationJashin J Wu, 1 Alexander Egeberg, 2 James A Solomon, 3,4,5 Olawale Osuntokun, 6 Orin Goldblum, 6 Susan R Moriarty, 6 Fangyi Zhao, 6 Neil Korman 7
4662 Ixekizumab Treatment Shows a Neutral Impact on the Glucose and Lipid Profile of Patients with Moderate-to-Severe Psoriasis: Results from UNCOVER-1, -2, and -3 Jashin J Wu, 1 Alexander Egeberg, 2 James
More informationRheumatology Advance Access published May 20, Immune responses to stress in rheumatoid arthritis and psoriasis
Concise report Rheumatology Advance Access published May 20, 2014 RHEUMATOLOGY 53, 263 doi:10.1093/rheumatology/keu221 Immune responses to stress in rheumatoid arthritis and psoriasis Sabine J. M. de Brouwer
More informationQuality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients
542 Quality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients XIAO-SHENG ZHUANG, YOU-YOU ZHENG, JIA-JIA XU and WEI-XIN FAN
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/142766
More informationLiterature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationQuality of Life of Patients with Lichen Simplex Chronicus
International Journal of Medicine and Pharmacy June 2016, Vol. 4, No. 1, pp. 53-60 ISSN 2372-5087 (Print) 2372-5095 (Online) Copyright The Author(s). All Rights Reserved. Published by American Research
More informationTopical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar
Topical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar Dr. Steven Feldman 1 Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands
More informationUNDERSTANDING ATOPIC DERMATITIS IN ITALY
UNDERSTANDING ATOPIC DERMATITIS IN Key points: Around 17% of people in Italy would have atopic dermatitis (AD) at some point in their life known as lifetime prevalence ; the disease is highly prevalent
More informationPatient Reported Quality of Life in an Early Psoriatic Arthritis Cohort
26 Patient Reported Quality of Life in an Early Psoriatic Arthritis Cohort Majed Khraishi 1 2, Jennifer Hulburt, Sarah Khraishi and Courtney Youden 2 1 Memorial University of Newfoundland, St. John s,
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationResearch Developments in Psoriasis Treatment A CME Activity
Overview Research Developments in Psoriasis Treatment A CME Activity Mark Lebwohl, MD, Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, provides his perspectives
More informationMark G. Lebwohl 1 Arthur Kavanaugh
Am J Clin Dermatol (2016) 17:87 97 DOI 10.1007/s40257-015-0169-x ORIGINAL RESEARCH ARTICLE US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the
More informationKim A. Papp, MD PhD Probity Medical Research, Waterloo, ON, Canada
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pooled Efficacy Results from the Subgroup of Canadian Patients in Two Phase III Randomized Controlled
More informationMarch 9, 2015 From: The Pediatric Dermatology Research Alliance (PeDRA)
Web: www.pedraresearch.org From: The Pediatric Dermatology Research Alliance (PeDRA) To: Jennifer Shepherd, Center for Drug Evaluation and Research Food and Drug Administration, 10903 New Hampshire Ave.,
More informationThe Changing Landscape of Psoriasis: New Horizons for Oral Therapies
The Changing Landscape of Psoriasis: New Horizons for Oral Therapies This symposium took place on 14 th September 2017, as part of the 26th European Academy of Dermatology and Venerology (EADV) Congress
More informationQuality of Life and Emotional State in Chronic Skin Disease
Acta Derm Venereol 2015; 95: 312 316 CLINICAL REPORT Quality of Life and Emotional State in Chronic Skin Disease Ene PÄRNA 1, Anu ALUOJA 2 and Külli KINGO 1, 3 1 Dermatology Clinic, Tartu University Clinics,
More informationEconomic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States
1142 Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States Tom Tencer, PhD 1 ; Zoe Clancy, PharmD, MS 1 ; Vidya Damera, MS 2 ; Frank Zhang MD, MPH 1 ;
More informationQuality of Life of Saudi Patients with Dermatologic Disorders
Clinical Medicine and Diagnostics 2018, 8(1): 1-6 DOI: 10.5923/j.cmd.20180801.01 Quality of Life of Saudi Patients with Dermatologic Disorders Bassam Ahmed Almutlaq 1, Fatemah Kadhem Aljishi 2, Rawan Ahmed
More informationWhat s new in psoriasis? An analysis of guidelines and systematic reviews published in
Clinical dermatology Review article CED Clinical and Experimental Dermatology CPD What s new in psoriasis? An analysis of guidelines and systematic reviews published in 2009 2010 A. C. Foulkes, D. J. C.
More informationCalcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
Am J Clin Dermatol (17) 18:5 411 DOI.7/s257-17-258- ORIGINAL RESEARCH ARTICLE Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis
More informationDimethyl Fumarate in Psoriasis Therapy
Dimethyl Fumarate in Psoriasis Therapy This meeting took place on 12 th October 2018, as part of the 2 nd European Workshop on Skin Immune Mediated Inflammatory Diseases (SIMID) in Verona, Italy Speakers:
More informationTRAUMA AND PTSD ASSESSMENT AND INTERVENTION. Brooks Keeshin, MD University of Utah
TRAUMA AND PTSD ASSESSMENT AND INTERVENTION Brooks Keeshin, MD University of Utah Disclosures I receive funding from SAMHSA and Utah Department of Health, Uppsala University and Hunter College. I receive
More informationTitle: The ideal target for psoriatic arthritis? Comparison of remission and low
Title: The ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real life cohort. Leonieke J.J. van Mens, MD 1, Marleen G.H. van de Sande, MD 1, PhD 1, Arno
More informationTranslating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment
Translating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment This symposium took place on 12 th October 2018, as part of the 2 nd European Workshop on Skin Immune Mediated Inflammatory
More informationPediatric Psoriasis Comorbidities. Kelly M. Cordoro, M.D. Associate Professor of Dermatology and Pediatrics University of California, San Francisco
Pediatric Psoriasis Comorbidities Kelly M. Cordoro, M.D. Associate Professor of Dermatology and Pediatrics University of California, San Francisco log2 (Expression/hARP) Th1 CXCL10 Disclosures * *** **
More informationMOR106, an anti-il-17c mab, a potential new approach for treatment of moderate-tosevere atopic dermatitis: Phase 1 study
, an anti-il-17c mab, a potential new approach for treatment of moderate-tosevere atopic dermatitis: Phase 1 study Diamant Thaçi 1, Maria Magdalena Constantin 2, Bernadette Rojkovich 3, Helen Timmis 4,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/184052
More informationAbstract Background: Methods: Results: Conclusion:
1055 Two-Year Safety of, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Psoriasis: Results From a Phase 3, Randomized, Controlled Trial () Kim A. Papp, MD 1 ; Kristian Reich,
More information6/17/2018. Comorbidities in Hidradenitis: Fact or Fiction. What is the best estimate of the rate of arthropathy for people with HS?
Comorbidities in Hidradenitis: Fact or Fiction Joslyn S. Kirby, MD, MS, MEd Department of Dermatology Penn State Milton S. Hershey Medical Center, Hershey PA Conflicts & Financial Disclosures for HS: AbbVie:
More informationInternational DErmatology Outcomes Measures. Modeled after OMERACT: Outcomes Measures in Rheumatology
International DErmatology Outcomes Measures Modeled after OMERACT: Outcomes Measures in Rheumatology 1992 original intent: obtain agreement on the minimum number of outcome measures to be included in all
More informationSecukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Adv Ther (2017) 34:1327 1339 DOI 10.1007/s12325-017-0521-z ORIGINAL RESEARCH is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? CLINICAL TRIALS
CLINICAL TRIALS BJD British Journal of Dermatology A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderateto-severe chronic plaque-type psoriasis: the Psoriasis
More information